# EDGAR Filing Document

**Accession Number:** 0001129928
**File Stem:** 0001129928-25-000066
**Filing Date:** 2025-8
**Character Count:** 32030
**Document Hash:** d388797954a15f5def33f26354254b85
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001129928-25-000066.hdr.sgml**: 20250808

**ACCESSION NUMBER**: 0001129928-25-000066

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250808

**FILED AS OF DATE**: 20250808

**DATE AS OF CHANGE**: 20250808

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ONCOLYTICS BIOTECH INC
- **CENTRAL INDEX KEY:** 0001129928
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38512
- **FILM NUMBER:** 251196600

**BUSINESS ADDRESS:**
- **STREET 1:** 804, 322 - 11 AVENUE SW
- **CITY:** CALGARY
- **STATE:** A0
- **ZIP:** T2R 0C5
- **BUSINESS PHONE:** 4036707380

**MAIL ADDRESS:**
- **STREET 1:** 804, 322 - 11 AVENUE SW
- **CITY:** CALGARY
- **STATE:** A0
- **ZIP:** T2R 0C5

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Form 6-K**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16**

**of the Securities Exchange Act of 1934**

For the month of August 2025

Commission File Number 001-38512

**Oncolytics Biotech Inc.**

*(Translation of registrant's name into English)*

**Suite 804, 322 11th Avenue SW**

**Calgary, Alberta, Canada T2R 0C5**

*(Address of principal executive offices)*

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F 🗹 Form 40-F □

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): □

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): □

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

------

---

| | |
|:---|:---|
| **EXHIBIT<br>NUMBER** | **DESCRIPTION** |
| 99.1 | <u>[Press Release](oncyq225prtoac-v7.htm)</u> |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **Oncolytics Biotech Inc.**<br>(Registrant) | **Oncolytics Biotech Inc.**<br>(Registrant) |
|  | By: | /s/ *Kirk Look*  |
| Date: August 8, 2025 |  | Kirk Look<br>Chief Financial Officer |

---

## Exhibit 99.1

**Oncolytics Biotech**<sup>®</sup> **Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep**

*Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study*

*New members of the management team bring expertise in progressing clinical programs and executing successful biotech transactions*

*Translational data further elucidate pelareorep's mechanism of action and ability to prime the tumor microenvironment for treatment*

*Commitment to limiting dilution evidenced by termination of At-the-Market and Equity Line of Credit facilities*

**SAN DIEGO, CA, August 8, 2025 –** Oncolytics Biotech<sup>®</sup> Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today reported financial results and recent highlights for the second quarter of 2025. All dollar amounts are expressed in Canadian currency unless otherwise noted.

"We have turned the corner from proof-of-concept studies and will be sprinting toward regulatory clarity for the remainder of the year," said Jared Kelly, Chief Executive Officer of Oncolytics. "As we shore up our intellectual property, get a clear registration path for pelareorep, and allow our GOBLET data to mature, we will establish our position as the only platform immunotherapy in gastrointestinal tumors."

**<u>Second Quarter and Subsequent Highlights</u>**

***Poster presentation at the American Society of Clinical Oncology Annual Meeting features translational data further demonstrating pelareorep's mechanism of action***. Additional analyses of the combination of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab in first-line ("1L") metastatic pancreatic ductal adenocarcinoma ("mPDAC") patients enhance the understanding of pelareorep's ability to stimulate the immune system and enable treatment regimens to be effective in a traditionally hostile tumor microenvironment (<u>click here for the PR</u>, <u>click here for the poster</u>). Pelareorep expands reovirus-specific T cells, increases cytokines and chemokines, and increases tumor-infiltrating lymphocytes ("TILs") in the blood.

***New Chief Executive Officer Jared Kelly and Chief Business Officer Andrew Aromando hired to optimize pelareorep's development path***. Both are experienced biotech executives with decades of experience advising companies, advancing clinical programs, and navigating successful transactions. They were both instrumental in guiding the sale of Ambrx Biopharma to Johnson & Johnson.

***Analyses of clinical data show pelareorep's ability to improve survival, and translational data confirming how the intended benefits are achieved***. Recently highlighted survival data in mPDAC and breast cancer point to meaningful survival benefits for patients treated with pelareorep-based regimens compared to either control arms or historical data (<u>click here for the PR</u>). In 1L mPDAC, a review of landmark studies shows a historical benchmark of 9.2% two-year survival for chemotherapy regimens, in contrast to the 21.9% two-year survival rate recorded for 100 patients receiving pelareorep and chemotherapy. Translational data from multiple studies and tumor types provide evidence as to how these impressive results have been achieved (<u>click here for the PR</u>). In the GOBLET and AWARE-1 studies, pelareorep converted immunologically "cold" tumors to "hot" ones as a result of the upregulation of interferons, CXCL9/10/11, and PD-L1 in addition to the expansion and mobilization of TILs in the blood, which is correlated with a reduction in tumor size.

------

***Key Opinion Leader ("KOL") webinar discussion solidifies pelareorep's opportunity in mPDAC and other gastrointestinal cancers***. Presentations from KOLs and a roundtable discussion of pelareorep's clinical data in mPDAC and gastrointestinal cancers point to a potentially significant opportunity for an immunotherapeutic drug candidate that already has shown the ability to extend survival for patients (<u>click here for the PR</u>). Specifically, 1L mPDAC would be ideal for pelareorep as there are no immunotherapies approved for that line of treatment, multiple 1L studies have already demonstrated pelareorep's ability to improve survival in that patient population, and it is backed up by translational data showing the ability to activate the immune system and alter the tumor microenvironment so it is more amenable to therapeutic intervention.

***Strategic decision to pursue registration-enabling pivotal study for pelareorep in 1L mPDAC***. Discussions with regulators are underway to finalize the approval pathway for pelareorep in 1L mPDAC (<u>click here for the PR</u>). This includes decisions on which treatment regimens will be involved, whether to collaborate with a third party on the study, and formalizing overall survival as the primary endpoint. The prioritization of the pancreatic cancer program is based on the compelling survival and translational data from previous studies involving over 100 patients, and the particularly high unmet medical need in this indication. Pelareorep has already received Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration (the "FDA") for mPDAC. If discussions with regulators proceed as expected and the feedback is positive, start-up activities for the study are expected to commence as early as Q4 2025.

***Commitment to limiting dilutive financing and maximizing shareholder value***. Oncolytics intends to terminate its At-the-Market financing facility with Cantor Fitzgerald and Equity Line of Credit with Alumni Capital. The Company believes it has sufficient capital to reach critical regulatory and clinical milestones this fall and pursue strategic opportunities that demonstrate pelareorep's potential without the need for near-term dilutive financings at this time. Additionally, as separately announced, the Company has given formal notice to delist from the Toronto Stock Exchange (the "TSX"). Once delisted from the TSX, the Company's common shares will continue to trade under the symbol "ONCY" on the Nasdaq.

**Financial Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• As of June 30, 2025, the Company reported $14.6 million in cash and cash equivalents, projecting a cash runway through key milestones and into the first quarter of 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The net loss for the second quarter of 2025 was $6.2 million, compared to a net loss of $7.3 million for the second quarter of 2024. The basic and diluted loss per share was $0.07 in the second quarter of 2025, compared to a basic and diluted loss per share of $0.10 in the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Research and development ("R&D") expenses for the second quarter of 2025 were $2.8 million, compared to $4.6 million for the second quarter of 2024. The decrease was primarily attributable to lower clinical trial expenses as the Company focused its R&D efforts on Cohort 5 of the GOBLET study, which is supported by the Pancreatic Cancer Action Network ("PanCAN") Therapeutic Accelerator Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• General and administrative expenses for the second quarter of 2025 were $2.9 million, compared to $3.4 million for the second quarter of 2024. The decrease was primarily due to lower public company-related expenses, and partially offset by higher personnel-related expenses associated with changes to the management team.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net cash used in operating activities for the six months ended June 30, 2025, was $12.0 million, compared to $14.3 million for the six months ended June 30, 2024. The decrease reflected lower operating activities in 2025, partially offset by higher non-cash working capital changes.

**Anticipated Milestones**

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Q3 2025: Provide an updated clinical timeline for the registration-enabling pivotal study for pelareorep in 1L mPDAC.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• As early as Q4 2025: Initiate start-up activities for the registration-enabling study for pelareorep in 1L mPDAC.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• End of 2025: Updated clinical data regarding safety and efficacy in Cohort 4 of the GOBLET study investigating pelareorep combined with atezolizumab in anal carcinoma.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Q4 2025: Initial responses from the U.S. Patent and Trademark Office ("PTO") regarding the company's application to extend patent protection for pelareorep.

**Annual General Meeting and Conference Call Change**

Management is hosting the Annual General Meeting later today at 10:00 a.m. ET, August 8, 2025. Oncolytics' Chief Executive Officer, Jared Kelly, will provide a brief update after the formal portion of the meeting. To access the meeting as a guest (*i.e.*, a non-voting shareholder):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Visit the webcast site: <u>https://virtual-meetings.tsxtrust.com/en/1824/</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Click the button "I am a Guest" and complete the form

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If necessary, provide the case-sensitive password: onc2025

Information on how to vote your shares by proxy and attend the meeting as a shareholder is available in the Company's most recent Management Information Circular (the "Circular") dated June 18, 2025. The Circular is available on the Reports page of the investor relations section of the Company's website at <u>https://oncolyticsbiotech.com/investor-overview/filings/reports/</u> and in Canadian and American securities filings.

Going forward, Oncolytics will continue to announce quarterly financial results via press releases and in securities filings, but will no longer host quarterly conference calls with the management team.

------

**ONCOLYTICS BIOTECH INC.**

**CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**

**(unaudited)**

(in thousands of Canadian dollars, except share amounts)

---

| | | |
|:---|:---|:---|
| As at | **June 30,**<br>**2025** | **December 31,**<br>**2024** |
| **Assets** |  |  |
| **Current assets** |  |  |
| Cash and cash equivalents | **$&nbsp;&nbsp;&nbsp;&nbsp;14626&nbsp;&nbsp;&nbsp;&nbsp;** | $&nbsp;&nbsp;&nbsp;&nbsp;15942&nbsp;&nbsp;&nbsp;&nbsp; |
| Other receivables | **&nbsp;&nbsp;&nbsp;&nbsp;72&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;68&nbsp;&nbsp;&nbsp;&nbsp; |
| Prepaid expenses | **&nbsp;&nbsp;&nbsp;&nbsp;3174&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;1885&nbsp;&nbsp;&nbsp;&nbsp; |
| Warrant derivative | **&nbsp;&nbsp;&nbsp;&nbsp;1024&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;980&nbsp;&nbsp;&nbsp;&nbsp; |
| **Total current assets** | **&nbsp;&nbsp;&nbsp;&nbsp;18896&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;18875&nbsp;&nbsp;&nbsp;&nbsp; |
| Property and equipment | **&nbsp;&nbsp;&nbsp;&nbsp;351&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;411&nbsp;&nbsp;&nbsp;&nbsp; |
| Right-of-use assets | **&nbsp;&nbsp;&nbsp;&nbsp;727&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;901&nbsp;&nbsp;&nbsp;&nbsp; |
| **Total assets** | **$&nbsp;&nbsp;&nbsp;&nbsp;19974&nbsp;&nbsp;&nbsp;&nbsp;** | $&nbsp;&nbsp;&nbsp;&nbsp;20187&nbsp;&nbsp;&nbsp;&nbsp; |
| **Liabilities and Shareholders' Equity** |  |  |
| **Current liabilities** |  |  |
| Accounts payable and accrued liabilities | **$&nbsp;&nbsp;&nbsp;&nbsp;5285&nbsp;&nbsp;&nbsp;&nbsp;** | $&nbsp;&nbsp;&nbsp;&nbsp;4792&nbsp;&nbsp;&nbsp;&nbsp; |
| Other liabilities | **&nbsp;&nbsp;&nbsp;&nbsp;982&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;1618&nbsp;&nbsp;&nbsp;&nbsp; |
| Lease liabilities | **&nbsp;&nbsp;&nbsp;&nbsp;291&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;277&nbsp;&nbsp;&nbsp;&nbsp; |
| **Total current liabilities** | **&nbsp;&nbsp;&nbsp;&nbsp;6558&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;6687&nbsp;&nbsp;&nbsp;&nbsp; |
| Contract liability | **&nbsp;&nbsp;&nbsp;&nbsp;6730&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;6730&nbsp;&nbsp;&nbsp;&nbsp; |
| Lease liabilities | **&nbsp;&nbsp;&nbsp;&nbsp;597&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;787&nbsp;&nbsp;&nbsp;&nbsp; |
| **Total liabilities** | **&nbsp;&nbsp;&nbsp;&nbsp;13885&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;14204&nbsp;&nbsp;&nbsp;&nbsp; |
| Commitments |  |  |
| **Shareholders' equity** |  |  |
| Share capital <br>&nbsp;&nbsp;&nbsp;&nbsp;Authorized: unlimited<br>&nbsp;&nbsp;&nbsp;&nbsp;Issued: June 30, 2025 – 97,407,903 <br>&nbsp;&nbsp;&nbsp;&nbsp;December 31, 2024 – 80,020,131 | **&nbsp;&nbsp;&nbsp;&nbsp;451142&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;438193&nbsp;&nbsp;&nbsp;&nbsp; |
| Contributed surplus | **&nbsp;&nbsp;&nbsp;&nbsp;44792&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;44542&nbsp;&nbsp;&nbsp;&nbsp; |
| Accumulated other comprehensive income | **&nbsp;&nbsp;&nbsp;&nbsp;720&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;961&nbsp;&nbsp;&nbsp;&nbsp; |
| Accumulated deficit | **&nbsp;&nbsp;&nbsp;&nbsp;(490565)** | &nbsp;&nbsp;&nbsp;&nbsp;(477713) |
| **Total shareholders' equity** | **&nbsp;&nbsp;&nbsp;&nbsp;6089&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;5983&nbsp;&nbsp;&nbsp;&nbsp; |
| **Total liabilities and shareholders' equity** | **$&nbsp;&nbsp;&nbsp;&nbsp;19974&nbsp;&nbsp;&nbsp;&nbsp;** | $&nbsp;&nbsp;&nbsp;&nbsp;20187&nbsp;&nbsp;&nbsp;&nbsp; |

---

------

**ONCOLYTICS BIOTECH INC.**

**CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS**

**(unaudited)**

(in thousands of Canadian dollars, except share amounts)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Expenses** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | **$&nbsp;&nbsp;&nbsp;&nbsp;2809&nbsp;&nbsp;&nbsp;&nbsp;** | $&nbsp;&nbsp;&nbsp;&nbsp;4558&nbsp;&nbsp;&nbsp;&nbsp; | **$&nbsp;&nbsp;&nbsp;&nbsp;6892&nbsp;&nbsp;&nbsp;&nbsp;** | $&nbsp;&nbsp;&nbsp;&nbsp;10301&nbsp;&nbsp;&nbsp;&nbsp; |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | **&nbsp;&nbsp;&nbsp;&nbsp;2897&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;3362&nbsp;&nbsp;&nbsp;&nbsp; | **&nbsp;&nbsp;&nbsp;&nbsp;5813&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;6345&nbsp;&nbsp;&nbsp;&nbsp; |
| **Loss before the following** | **&nbsp;&nbsp;&nbsp;&nbsp;(5706)** | &nbsp;&nbsp;&nbsp;&nbsp;(7920) | **&nbsp;&nbsp;&nbsp;&nbsp;(12705)** | &nbsp;&nbsp;&nbsp;&nbsp;(16646) |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of warrant derivative | **&nbsp;&nbsp;&nbsp;&nbsp;(196)** | &nbsp;&nbsp;&nbsp;&nbsp;235&nbsp;&nbsp;&nbsp;&nbsp; | **&nbsp;&nbsp;&nbsp;&nbsp;44&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;1104&nbsp;&nbsp;&nbsp;&nbsp; |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange (loss) gain | **&nbsp;&nbsp;&nbsp;&nbsp;(282)** | &nbsp;&nbsp;&nbsp;&nbsp;184&nbsp;&nbsp;&nbsp;&nbsp; | **&nbsp;&nbsp;&nbsp;&nbsp;(333)** | &nbsp;&nbsp;&nbsp;&nbsp;701&nbsp;&nbsp;&nbsp;&nbsp; |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income, net | **&nbsp;&nbsp;&nbsp;&nbsp;104&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;340&nbsp;&nbsp;&nbsp;&nbsp; | **&nbsp;&nbsp;&nbsp;&nbsp;227&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;786&nbsp;&nbsp;&nbsp;&nbsp; |
| **Loss before income taxes** | **&nbsp;&nbsp;&nbsp;&nbsp;(6080)** | &nbsp;&nbsp;&nbsp;&nbsp;(7161) | **&nbsp;&nbsp;&nbsp;&nbsp;(12767)** | &nbsp;&nbsp;&nbsp;&nbsp;(14055) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | **&nbsp;&nbsp;&nbsp;&nbsp;(85)** | &nbsp;&nbsp;&nbsp;&nbsp;(95) | **&nbsp;&nbsp;&nbsp;&nbsp;(85)** | &nbsp;&nbsp;&nbsp;&nbsp;(95) |
| **Net loss** | **&nbsp;&nbsp;&nbsp;&nbsp;(6165)** | &nbsp;&nbsp;&nbsp;&nbsp;(7256) | **&nbsp;&nbsp;&nbsp;&nbsp;(12852)** | &nbsp;&nbsp;&nbsp;&nbsp;(14150) |
| **Other comprehensive (loss) income items that may be reclassified to net loss** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Translation adjustment | **&nbsp;&nbsp;&nbsp;&nbsp;(238)** | &nbsp;&nbsp;&nbsp;&nbsp;52&nbsp;&nbsp;&nbsp;&nbsp; | **&nbsp;&nbsp;&nbsp;&nbsp;(241)** | &nbsp;&nbsp;&nbsp;&nbsp;178&nbsp;&nbsp;&nbsp;&nbsp; |
| **Comprehensive loss** | **$&nbsp;&nbsp;&nbsp;&nbsp;(6403)** | $&nbsp;&nbsp;&nbsp;&nbsp;(7204) | **$&nbsp;&nbsp;&nbsp;&nbsp;(13093)** | $&nbsp;&nbsp;&nbsp;&nbsp;(13972) |
| **Basic and diluted loss per common share** | **$&nbsp;&nbsp;&nbsp;&nbsp;(0.07)** | $&nbsp;&nbsp;&nbsp;&nbsp;(0.10) | **$&nbsp;&nbsp;&nbsp;&nbsp;(0.15)** | $&nbsp;&nbsp;&nbsp;&nbsp;(0.19) |
| **Weighted average number of shares (basic and diluted)** | **&nbsp;&nbsp;&nbsp;&nbsp;90999586&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;76090406&nbsp;&nbsp;&nbsp;&nbsp; | **&nbsp;&nbsp;&nbsp;&nbsp;87833107&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;75667521&nbsp;&nbsp;&nbsp;&nbsp; |

---

*&nbsp;&nbsp;&nbsp;&nbsp;*

------

**ONCOLYTICS BIOTECH INC.**

**CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY**

**(unaudited)**

(in thousands of Canadian dollars)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Share Capital** | **Contributed Surplus** | **Accumulated Other Comprehensive Income** | **Accumulated Deficit** | **Total** |
| As at December 31, 2023 | $&nbsp;&nbsp;&nbsp;&nbsp;430906&nbsp;&nbsp;&nbsp;&nbsp; | $&nbsp;&nbsp;&nbsp;&nbsp;42116&nbsp;&nbsp;&nbsp;&nbsp; | $&nbsp;&nbsp;&nbsp;&nbsp;544&nbsp;&nbsp;&nbsp;&nbsp; | $&nbsp;&nbsp;&nbsp;&nbsp;(446003) | $&nbsp;&nbsp;&nbsp;&nbsp;27563&nbsp;&nbsp;&nbsp;&nbsp; |
| Net loss and other comprehensive income | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;178&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;(14150) | &nbsp;&nbsp;&nbsp;&nbsp;(13972) |
| Issued pursuant to incentive share award plan | &nbsp;&nbsp;&nbsp;&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;(3) | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; |
| Issued pursuant to "At the Market" Agreement | &nbsp;&nbsp;&nbsp;&nbsp;3840&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;3840&nbsp;&nbsp;&nbsp;&nbsp; |
| Share issue costs | &nbsp;&nbsp;&nbsp;&nbsp;(202) | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;(202) |
| Share-based compensation expense | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;1082&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;1082&nbsp;&nbsp;&nbsp;&nbsp; |
| **As at June 30, 2024** | $&nbsp;&nbsp;&nbsp;&nbsp;434547&nbsp;&nbsp;&nbsp;&nbsp; | $&nbsp;&nbsp;&nbsp;&nbsp;43195&nbsp;&nbsp;&nbsp;&nbsp; | $&nbsp;&nbsp;&nbsp;&nbsp;722&nbsp;&nbsp;&nbsp;&nbsp; | $&nbsp;&nbsp;&nbsp;&nbsp;(460153) | $&nbsp;&nbsp;&nbsp;&nbsp;18311&nbsp;&nbsp;&nbsp;&nbsp; |
| As at December 31, 2024 | $&nbsp;&nbsp;&nbsp;&nbsp;438193&nbsp;&nbsp;&nbsp;&nbsp; | $&nbsp;&nbsp;&nbsp;&nbsp;44542&nbsp;&nbsp;&nbsp;&nbsp; | $&nbsp;&nbsp;&nbsp;&nbsp;961&nbsp;&nbsp;&nbsp;&nbsp; | $&nbsp;&nbsp;&nbsp;&nbsp;(477713) | $&nbsp;&nbsp;&nbsp;&nbsp;5983&nbsp;&nbsp;&nbsp;&nbsp; |
| Net loss and other comprehensive loss | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;(241) | &nbsp;&nbsp;&nbsp;&nbsp;(12852) | &nbsp;&nbsp;&nbsp;&nbsp;(13093) |
| Issued pursuant to incentive share award plan | &nbsp;&nbsp;&nbsp;&nbsp;1481&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;(1481) | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; |
| Issued pursuant to "At the Market" Agreement | &nbsp;&nbsp;&nbsp;&nbsp;8714&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;8714&nbsp;&nbsp;&nbsp;&nbsp; |
| Issued pursuant to share purchase agreement | &nbsp;&nbsp;&nbsp;&nbsp;3841&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;3841&nbsp;&nbsp;&nbsp;&nbsp; |
| Share issue costs | &nbsp;&nbsp;&nbsp;&nbsp;(1087) | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;(1087) |
| Share-based compensation expense | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;1731&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;1731&nbsp;&nbsp;&nbsp;&nbsp; |
| **As at June 30, 2025** | **$&nbsp;&nbsp;&nbsp;&nbsp;451142&nbsp;&nbsp;&nbsp;&nbsp;** | **$&nbsp;&nbsp;&nbsp;&nbsp;44792&nbsp;&nbsp;&nbsp;&nbsp;** | **$&nbsp;&nbsp;&nbsp;&nbsp;720&nbsp;&nbsp;&nbsp;&nbsp;** | **$&nbsp;&nbsp;&nbsp;&nbsp;(490565)** | **$&nbsp;&nbsp;&nbsp;&nbsp;6089&nbsp;&nbsp;&nbsp;&nbsp;** |

---

------

**ONCOLYTICS BIOTECH INC.**

**CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(unaudited)**

(in thousands of Canadian dollars)

---

| | | |
|:---|:---|:---|
| | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** |
| **Operating Activities** |  |  |
| Net loss for the period | **$&nbsp;&nbsp;&nbsp;&nbsp;(12852)** | $&nbsp;&nbsp;&nbsp;&nbsp;(14150) |
| Depreciation - property and equipment | **&nbsp;&nbsp;&nbsp;&nbsp;51&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;56&nbsp;&nbsp;&nbsp;&nbsp; |
| Depreciation - right-of-use-assets | **&nbsp;&nbsp;&nbsp;&nbsp;140&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;165&nbsp;&nbsp;&nbsp;&nbsp; |
| Share-based compensation expense | **&nbsp;&nbsp;&nbsp;&nbsp;1731&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;1082&nbsp;&nbsp;&nbsp;&nbsp; |
| Interest expense on lease liabilities | **&nbsp;&nbsp;&nbsp;&nbsp;74&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;57&nbsp;&nbsp;&nbsp;&nbsp; |
| Unrealized foreign exchange loss (gain) | **&nbsp;&nbsp;&nbsp;&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;(576) |
| Change in fair value of warrant derivative | **&nbsp;&nbsp;&nbsp;&nbsp;(44)** | &nbsp;&nbsp;&nbsp;&nbsp;(1104) |
| Net change in non-cash working capital | **&nbsp;&nbsp;&nbsp;&nbsp;(1070)** | &nbsp;&nbsp;&nbsp;&nbsp;182&nbsp;&nbsp;&nbsp;&nbsp; |
| **Cash used in operating activities** | **&nbsp;&nbsp;&nbsp;&nbsp;(11969)** | &nbsp;&nbsp;&nbsp;&nbsp;(14288) |
| **Investing Activities** |  |  |
| Acquisition of property and equipment | **&nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;(201) |
| **Cash used in investing activities** | **&nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;(201) |
| **Financing Activities** |  |  |
| Proceeds from "At the Market" equity distribution agreement, net | **&nbsp;&nbsp;&nbsp;&nbsp;8386&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;3638&nbsp;&nbsp;&nbsp;&nbsp; |
| Proceeds from share purchase agreement, net | **&nbsp;&nbsp;&nbsp;&nbsp;3082&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;—&nbsp;&nbsp;&nbsp;&nbsp; |
| Payment of lease liabilities | **&nbsp;&nbsp;&nbsp;&nbsp;(205)** | &nbsp;&nbsp;&nbsp;&nbsp;(168) |
| **Cash provided by financing activities** | **&nbsp;&nbsp;&nbsp;&nbsp;11263&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;3470&nbsp;&nbsp;&nbsp;&nbsp; |
| **Decrease in cash and cash equivalents** | **&nbsp;&nbsp;&nbsp;&nbsp;(706)** | &nbsp;&nbsp;&nbsp;&nbsp;(11019) |
| Cash and cash equivalents, beginning of period | **&nbsp;&nbsp;&nbsp;&nbsp;15942&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;&nbsp;&nbsp;34912&nbsp;&nbsp;&nbsp;&nbsp; |
| Impact of foreign exchange on cash and cash equivalents | **&nbsp;&nbsp;&nbsp;&nbsp;(610)** | &nbsp;&nbsp;&nbsp;&nbsp;957&nbsp;&nbsp;&nbsp;&nbsp; |
| **Cash and cash equivalents, end of period** | **$&nbsp;&nbsp;&nbsp;&nbsp;14626&nbsp;&nbsp;&nbsp;&nbsp;** | $&nbsp;&nbsp;&nbsp;&nbsp;24850&nbsp;&nbsp;&nbsp;&nbsp; |

---

**About Oncolytics Biotech Inc.**

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer and early-phase studies in anal and colorectal cancer. It induces anti-cancer immune responses by converting immunologically "cold" tumors "hot" through the activation of innate and adaptive immune responses.

The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the

<br> <br> <br>

------

FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: <u>www.oncolyticsbiotech.com</u> or follow the Company on social media on <u>LinkedIn</u> and on X @<u>oncolytics</u>.

**Forward-looking statements**

*This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; its upcoming milestones; its belief that we will establish our position as the only platform immunotherapy in gastrointestinal tumors; its plans for a potential registration-enabling pivotal study in 1L mPDAC; the anticipated potential timing of commencement of start-up activities and enrollment in a study; the focus of its discussions with the FDA in respect of the study; the anticipated trial design; its plan to delist from the Toronto Stock Exchange; its plans with respect to shareholder communications; and its plan to continue actively pursuing strategic partnerships; its goals, strategies and objectives; its belief in the clinical promise of pelareorep in mPDAC and other gastrointestinal cancers; financial projections and the sufficiency of capital to reach critical milestones and pursue strategic opportunities and its need for near-term dilutive financing. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics' public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.*

**Company Contact** 

Jon Patton

Director of IR & Communication

jpatton@oncolytics.ca

**Investor Relations for Oncolytics**

Mike Moyer

LifeSci Advisors

+1-617-308-4306

mmoyer@lifesciadvisors.com

**Media Contact for Oncolytics**

Owen Blaschak

LifeSci Communications

oblaschak@lifescicomms.com

<br> <br> <br>

<br>